Q2 2025 Earnings Estimate for Avid Bioservices, Inc. Issued By William Blair (NASDAQ:CDMO)

Avid Bioservices, Inc. (NASDAQ:CDMO) – Investment analysts at William Blair dropped their Q2 2025 EPS estimates for Avid Bioservices in a research note issued to investors on Tuesday, September 10th. William Blair analyst M. Smock now expects that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter, down from their previous estimate of ($0.12). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Avid Bioservices’ current full-year earnings is ($0.31) per share. William Blair also issued estimates for Avid Bioservices’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.34) EPS and FY2026 earnings at ($0.18) EPS.

Several other research firms have also recently issued reports on CDMO. Royal Bank of Canada increased their price target on Avid Bioservices from $8.00 to $12.00 and gave the stock an “outperform” rating in a research note on Tuesday. StockNews.com upgraded shares of Avid Bioservices to a “sell” rating in a research report on Tuesday. Finally, Stephens restated an “overweight” rating and set a $12.00 price target on shares of Avid Bioservices in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Avid Bioservices has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Avid Bioservices Stock Performance

Shares of CDMO stock opened at $11.16 on Friday. The business has a 50 day simple moving average of $9.97 and a 200 day simple moving average of $8.35. The company has a debt-to-equity ratio of 2.74, a current ratio of 1.46 and a quick ratio of 0.31. The firm has a market capitalization of $711.90 million, a price-to-earnings ratio of -5.05 and a beta of 1.37. Avid Bioservices has a 12-month low of $4.07 and a 12-month high of $11.57.

Avid Bioservices (NASDAQ:CDMO) last posted its earnings results on Tuesday, July 2nd. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.10). Avid Bioservices had a negative net margin of 101.26% and a negative return on equity of 16.53%. The firm had revenue of $42.98 million for the quarter, compared to analyst estimates of $42.60 million.

Insider Activity

In related news, CEO Nicholas Stewart Green sold 7,657 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $7.54, for a total value of $57,733.78. Following the completion of the transaction, the chief executive officer now owns 212,314 shares in the company, valued at approximately $1,600,847.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 9,216 shares of company stock worth $69,984. Insiders own 2.39% of the company’s stock.

Institutional Investors Weigh In On Avid Bioservices

Several hedge funds have recently made changes to their positions in CDMO. Millennium Management LLC grew its position in Avid Bioservices by 15.8% during the 2nd quarter. Millennium Management LLC now owns 5,099,529 shares of the biopharmaceutical company’s stock worth $36,411,000 after purchasing an additional 695,512 shares in the last quarter. Vanguard Group Inc. raised its position in Avid Bioservices by 1.3% during the first quarter. Vanguard Group Inc. now owns 3,665,188 shares of the biopharmaceutical company’s stock valued at $24,557,000 after buying an additional 47,315 shares during the period. AltraVue Capital LLC lifted its stake in Avid Bioservices by 7.6% in the 2nd quarter. AltraVue Capital LLC now owns 3,395,263 shares of the biopharmaceutical company’s stock worth $24,242,000 after acquiring an additional 239,343 shares in the last quarter. 12 West Capital Management LP acquired a new stake in Avid Bioservices during the 1st quarter worth about $18,425,000. Finally, Point72 Asset Management L.P. grew its stake in Avid Bioservices by 51.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,673,050 shares of the biopharmaceutical company’s stock valued at $19,086,000 after acquiring an additional 904,733 shares in the last quarter. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Avid Bioservices Company Profile

Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.